Cure My Disease

Don't miss your cure!

 Log in / Sign up

Silencing the gene: new trial aims to stop debilitating swelling attacks

NCT ID NCT06960213

Recruiting now Disease control Sponsor: ADARx Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

Summary

This study is testing a new drug called ADX-324 to see if it can prevent the sudden, painful swelling attacks caused by hereditary angioedema (HAE). It will involve about 90 adults with HAE who will receive either the drug or a placebo. The main goal is to see if the drug reduces the number of attacks participants experience each month.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • ADARx Clinical Site

    RECRUITING

    Little Rock, Arkansas, 72205, United States

  • ADARx Clinical Site

    RECRUITING

    Walnut Creek, California, 94598, United States

  • ADARx Clinical Site

    RECRUITING

    Wheaton, Maryland, 20902, United States

  • ADARx Clinical Site

    RECRUITING

    Detroit, Michigan, 48202, United States

  • ADARx Clinical Site

    RECRUITING

    St Louis, Missouri, 63141, United States

  • ADARx Clinical Site

    RECRUITING

    Las Vegas, Nevada, 89128, United States

  • ADARx Clinical Site

    RECRUITING

    New York, New York, 10029, United States

  • ADARx Clinical Site

    RECRUITING

    Cincinnati, Ohio, 45236, United States

  • ADARx Clinical Site

    RECRUITING

    Columbus, Ohio, 43235, United States

  • ADARx Clinical Site

    RECRUITING

    Toledo, Ohio, 43617, United States

  • ADARx Clinical Site

    RECRUITING

    Ottawa, Ontario, K1H 1E4, Canada

  • ADARx Clinical Site

    RECRUITING

    Hradec Králové, 500 05, Czechia

  • ADARx Clinical Site

    RECRUITING

    Budapest, 1088, Hungary

  • ADARx Clinical Site

    RECRUITING

    Madrid, 28007, Spain

Conditions

Explore the condition pages connected to this study.

HAE HEREDITARY ANGIOEDEMA HEREDITARY ANGIOEDEMA - TYPE 1 HEREDITARY ANGIOEDEMA - TYPE 2